Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Recent & Breaking News (GREY:ATBPF)

Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug

Business Wire July 31, 2018

Antibe Completes Share Issuance in Connection with Citagenix Credit Facility

Business Wire July 6, 2018

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346

Business Wire July 3, 2018

Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results

Business Wire June 29, 2018

Antibe Therapeutics Announces Results of Annual General and Special Meeting

Business Wire June 26, 2018

Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts

Business Wire June 4, 2018

Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine

Business Wire May 29, 2018

Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

Business Wire May 24, 2018

Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 30, 2018

Antibe Therapeutics Announces CEO Letter to Shareholders

Business Wire April 26, 2018

Antibe Therapeutics Engages Blaise Group International for Executive Search

Business Wire April 11, 2018

Antibe Therapeutics Provides Financial Update

Business Wire April 3, 2018

IIROC Trading Resumption - ATE

Canada NewsWire March 20, 2018

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346

Business Wire March 20, 2018

IIROC Trading Halt - ATE

Canada NewsWire March 19, 2018

Antibe Therapeutics Announces No Material Change

Business Wire March 13, 2018

Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results

Business Wire February 27, 2018

Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346

Business Wire February 26, 2018

Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346

Business Wire January 29, 2018

Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346

Business Wire January 17, 2018